Albany, New York, USA (PRWEB) November 01, 2013
According to a new market report published by Transparency Market Research "Atrial Fibrillation Market (Pharmacological and Non-Pharmacological Treatment, Electric Cardioversion, Radiofrequency, Cryo, Laser and Microwave Catheter Ablation, Maze Surgery, Anti-Coagulant and Anti-Arrhythmic Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global market for atrial fibrillation was valued at USD 6.1 billion in 2012 and it is expected to reach an estimated value of USD 14.8 billion in 2019, growing at a CAGR of 13.4 percent from 2013 to 2019.
Browse the full report with complete TOC at http://www.transparencymarketresearch.com/atrial-fibrillation-market.html.
Rising global base of geriatric population inducing an accelerated growth in the incidence rates of atrial fibrillation is one of the highest impact-rendering drivers for this market. In addition, favorable results exhibited by clinical trials promoting combined pharmacological therapy such as the HARMONY trial and rising prevalence of disorders causing atrial fibrillation such as hypertension and obesity will also serve the market as drivers. The future growth of this market will be ensured by the introduction of advanced treatment procedures such as hybrid ablation and the rising prevalence of atrial fibrillation in emerging Asian economies.
On account of the fact that pharmacological treatment procedures are more frequently administered to the patients suffering from atrial fibrillation and are a cheaper alternative to non-pharmacological procedures, pharmacological procedures held the majority of market share in 2012. With the introduction of new drugs such as Bristol Myer Squibb's NTC-801, Merck's Vernakalant, Boehringer Ingelheim's Pradaxa, the market share of pharmacological treatment procedures is expected to further increase by 2019.
The non-pharmacological treatment market was led by the catheter ablation market and its market share was valued at over 45 percent in 2012. The introduction of new catheter ablation systems, such as CardioFocus's HeartLight Endoscopic Ablation System (EAS) laser ablation catheter, Endosense's TactiCath and Biosense Webster's ThermoCool SmartTouch, will help the catheter ablation market to further enhance its market share by 2019.
The radiofrequency based catheter ablation treatment for atrial fibrillation market led the catheter ablation market in terms of market share in 2012 majorly on account of the facts that it has a relatively lower procedural duration and cost and has high success rates associated with it.
High prevalence of atrial fibrillation, coupled with the availability of high disposable incomes amongst patients and sophisticated healthcare infrastructure, has led the North American atrial fibrillation market to hold the majority of the market share in 2012. However, this region is expected to lose its market share to relatively faster growing Asia-Pacific region.
Some of the key players of this market include Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Bayer/Johnson & Johnson, Medtronic, Inc., St. Jude Medical, Inc. and AtriCure, Inc.
Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. Being a potentially life threatening disease and expensive to treat, the overall healthcare system views the treatment for this condition as a strategically critical area to address. This report analyzes the market for atrial fibrillation market from the point of view of various pharmacological and non-pharmacological treatment products used for the treatment of AF.
The pharmacological AF treatment market has been further classified into the specific drugs commonly used for treating AF, namely anti-arrythmics and anti-coagulants. The non-pharmacological atrial fibrillation devices market has been further sub-divided into therapeutic procedures such as catheter ablation procedures, maze surgery and electric cardioversion. The major methods of catheter ablation procedures studied in this report include radiofrequency, high intensity focused ultrasound (HIFU), cryoablation, microwave ablation and laser catheter ablation. Each of these segments and their sub-classification is analyzed on the basis of their market size and their forecast for the period 2011 to 2019, in terms of USD million.
Related Report : Medical Fiber Optics Market
The compounded annual growth rate (CAGR) for all the above segments has been provided for the forecast period from 2013 to 2019, considering 2012 as the base year. In terms of geography, the market for atrial fibrillation treatment has been categorized into four geographical markets namely, North America, Europe, Asia-Pacific and Rest of the World (RoW).
The market size and forecast for all the major segments, along with their growth rate, by regions has been provided in the report. The market overview section of the report includes the qualitative analysis of the atrial fibrillation treatment market in terms of environmental factors such as drivers, restraints and opportunities, market attractiveness analysis and Porter’s five forces analysis.
Read the full story at http://www.prweb.com/releases/2013/11/prweb11294058.htm.
Copyright©2012 Vocus, Inc.
All rights reserved